ONO-4578-04:ONO-4578 Phase 1 Study

ONO-4578-04:Phase 1 study of ONO-4578 given as combinations of ONO-4578, ONO-4538 and modified FOLFIRINOX or Gem/nab-PTX in subjects with metastatic pancreatic cancer(ONO-4578-04)

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2031200286

Enrollment

Registered

2021-01-06

Start date

2021-01-13

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

metastatic pancreatic cancer

Interventions

ONO-4578 given as combinations of ONO-4578, ONO-4538 and modified FOLFIRINOX or Gem/nab-PTX

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Pancreatic invasive ducatal adenocarcinoma 2. Life expectancy of at least 3 months 3. Patients with ECOG performance status 0 or 1

Exclusion criteria

Exclusion criteria: 1. Patients with severe complication 2. Patients with multiple primary cancers

Design outcomes

Primary

Measure	Time frame
Safety, tolerability	—

Contacts

Public ContactMedical Center

Ono Pharmaceutical Co.,LTD

clinical_trial@ono-pharma.com+81-120-626-190

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026